The ASA treatment caused a significant decrease (p < 0.0001) in the NLRP3 and IL-1β brain expression and was able to ameliorate the process of neuroinflammation and consequently the cognitive impairment induced by the administration of alcohol and/or ATOR. Here, NLRP3 is linked to Cognitive impairment.